These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19925641)

  • 1. Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains.
    O'Brien LM; Underwood-Fowler CD; Goodchild SA; Phelps AL; Phillpotts RJ
    Virol J; 2009 Nov; 6():206. PubMed ID: 19925641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III.
    Phillpotts RJ
    Virus Res; 2006 Sep; 120(1-2):107-12. PubMed ID: 16621103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus.
    Hunt AR; Frederickson S; Hinkel C; Bowdish KS; Roehrig JT
    J Gen Virol; 2006 Sep; 87(Pt 9):2467-2476. PubMed ID: 16894184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus.
    Phillpotts RJ; Jones LD; Howard SC
    Vaccine; 2002 Feb; 20(11-12):1497-504. PubMed ID: 11858855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A humanised murine monoclonal antibody protects mice from Venezuelan equine encephalitis virus, Everglades virus and Mucambo virus when administered up to 48 h after airborne challenge.
    O'Brien LM; Goodchild SA; Phillpotts RJ; Perkins SD
    Virology; 2012 May; 426(2):100-5. PubMed ID: 22341308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposing cryptic epitopes on the Venezuelan equine encephalitis virus E1 glycoprotein prior to treatment with alphavirus cross-reactive monoclonal antibody allows blockage of replication early in infection.
    Calvert AE; Bennett SL; Hunt AR; Fong RH; Doranz BJ; Roehrig JT; Blair CD
    Virology; 2022 Jan; 565():13-21. PubMed ID: 34626907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity.
    Hunt AR; Frederickson S; Maruyama T; Roehrig JT; Blair CD
    PLoS Negl Trop Dis; 2010 Jul; 4(7):e739. PubMed ID: 20644615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Preparations from Human Transchromosomic Cows Exhibit Prophylactic and Therapeutic Efficacy against Venezuelan Equine Encephalitis Virus.
    Gardner CL; Sun C; Luke T; Raviprakash K; Wu H; Jiao JA; Sullivan E; Reed DS; Ryman KD; Klimstra WB
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus.
    Goodchild SA; O'Brien LM; Steven J; Muller MR; Lanning OJ; Logue CH; D'Elia RV; Phillpotts RJ; Perkins SD
    Antiviral Res; 2011 Apr; 90(1):1-8. PubMed ID: 21310183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection.
    Hunt AR; Bowen RA; Frederickson S; Maruyama T; Roehrig JT; Blair CD
    Virology; 2011 Jun; 414(2):146-52. PubMed ID: 21489591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus.
    Hu WG; Phelps AL; Jager S; Chau D; Hu CC; O'Brien LM; Perkins SD; Gates AJ; Phillpotts RJ; Nagata LP
    Vaccine; 2010 Aug; 28(34):5558-64. PubMed ID: 20600509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection.
    O'Brien L; Perkins S; Williams A; Eastaugh L; Phelps A; Wu J; Phillpotts R
    J Gen Virol; 2009 Apr; 90(Pt 4):874-882. PubMed ID: 19264673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure.
    Braid LR; Hu WG; Davies JE; Nagata LP
    Stem Cells Transl Med; 2016 Aug; 5(8):1026-35. PubMed ID: 27334491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo.
    Rülker T; Voß L; Thullier P; O' Brien LM; Pelat T; Perkins SD; Langermann C; Schirrmann T; Dübel S; Marschall HJ; Hust M; Hülseweh B
    PLoS One; 2012; 7(5):e37242. PubMed ID: 22666347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection.
    Parker MD; Buckley MJ; Melanson VR; Glass PJ; Norwood D; Hart MK
    J Virol; 2010 Dec; 84(24):12683-90. PubMed ID: 20926570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV).
    Kirsch MI; Hülseweh B; Nacke C; Rülker T; Schirrmann T; Marschall HJ; Hust M; Dübel S
    BMC Biotechnol; 2008 Sep; 8():66. PubMed ID: 18764933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge.
    Henning L; Endt K; Steigerwald R; Anderson M; Volkmann A
    Front Immunol; 2020; 11():598847. PubMed ID: 33542715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine.
    Dupuy LC; Locher CP; Paidhungat M; Richards MJ; Lind CM; Bakken R; Parker MD; Whalen RG; Schmaljohn CS
    Vaccine; 2009 Jun; 27(31):4152-60. PubMed ID: 19406186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus.
    Elvin SJ; Bennett AM; Phillpotts RJ
    J Med Virol; 2002 Jul; 67(3):384-93. PubMed ID: 12116032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccinia virus recombinants encoding the truncated structural gene region of Venezuelan equine encephalitis virus (VEEV) give solid protection against peripheral challenge but only partial protection against airborne challenge with virulent VEEV.
    Phillpotts RJ; Lescott TL; Jacobs SC
    Acta Virol; 2000 Oct; 44(5):233-9. PubMed ID: 11252667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.